Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00348712
Other study ID # NN1998-1390
Secondary ID 2006-000796-15
Status Terminated
Phase Phase 3
First received July 5, 2006
Last updated February 28, 2017
Start date October 30, 2006
Est. completion date March 5, 2008

Study information

Verified date February 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is conducted in Europe.

The aim of this research study is to compare the efficacy of adding inhaled preprandial insulin to metformin compared to adding rosiglitazone to metformin for the treatment of type 2 diabetes and to verify its safety (hypoglycaemia, pulmonary function, body weight, insulin antibodies and side effects).


Description:

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.


Recruitment information / eligibility

Status Terminated
Enrollment 301
Est. completion date March 5, 2008
Est. primary completion date March 5, 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetes

- Treated with OAD(s) for more than or equal to 2 months

- Body mass index of (BMI) less than or equal to 40.0 kg/m2

- HbA1c greater than or equal to 7.5% and less than or equal to 11.0 % for subjects in OAD monotherapy and HbA1c greater than or equal to 7.0% and less than or equal to 10.0 % for subjects on OAD combination therapy

Exclusion Criteria:

- Recurrent major hypoglycaemia

- Current smoking or smoking within the last 6 months

- Impaired hepatic or renal function

- Cardiac disorders

- Uncontrolled hypertension

- Proliferative retinopathy or maculopathy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
rosiglitazone
Tablets, 4 mg once or twice daily.
inhaled human insulin
Treat-to-target dose titration scheme, inhalation.
metformin
Tablets, 2000 mg/day.

Locations

Country Name City State
Austria Novo Nordisk Investigational Site Ebreichsdorf
Austria Novo Nordisk Investigational Site Wien
Austria Novo Nordisk Investigational Site Wien
Finland Novo Nordisk Investigational Site Joensuu
Finland Novo Nordisk Investigational Site Kirkkonummi
Finland Novo Nordisk Investigational Site Turku
France Novo Nordisk Investigational Site Corbeil Essonnes
France Novo Nordisk Investigational Site LA ROCHELLE cedex
France Novo Nordisk Investigational Site Mougins
France Novo Nordisk Investigational Site Nanterre
France Novo Nordisk Investigational Site Narbonne
France Novo Nordisk Investigational Site NEVERS cedex
France Novo Nordisk Investigational Site Pessac
France Novo Nordisk Investigational Site Pointe à Pitre
France Novo Nordisk Investigational Site Roubaix
France Novo Nordisk Investigational Site Tours
France Novo Nordisk Investigational Site Venissieux
Germany Novo Nordisk Investigational Site Aschaffenburg
Germany Novo Nordisk Investigational Site Augsburg
Germany Novo Nordisk Investigational Site Bad Mergentheim
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Darmstadt
Germany Novo Nordisk Investigational Site Dormagen
Germany Novo Nordisk Investigational Site Dresden
Germany Novo Nordisk Investigational Site Duisburg
Germany Novo Nordisk Investigational Site Flörsheim
Germany Novo Nordisk Investigational Site Frankfurt
Germany Novo Nordisk Investigational Site Fulda
Germany Novo Nordisk Investigational Site Genthin
Germany Novo Nordisk Investigational Site Hermaringen
Germany Novo Nordisk Investigational Site Kutenholz-Mulsum
Germany Novo Nordisk Investigational Site Münster
Germany Novo Nordisk Investigational Site Pirna
Germany Novo Nordisk Investigational Site Schkeuditz
Germany Novo Nordisk Investigational Site Wangen
Germany Novo Nordisk Investigational Site Wiesbaden
Ireland Novo Nordisk Investigational Site Dublin
Ireland Novo Nordisk Investigational Site Dublin
Ireland Novo Nordisk Investigational Site Waterford
Netherlands Novo Nordisk Investigational Site Delft
Netherlands Novo Nordisk Investigational Site Den Haag
Netherlands Novo Nordisk Investigational Site Den Haag
Netherlands Novo Nordisk Investigational Site Drachten
Netherlands Novo Nordisk Investigational Site Rijswijk
Netherlands Novo Nordisk Investigational Site Roelofarendsveen
Netherlands Novo Nordisk Investigational Site Vlodrop
Netherlands Novo Nordisk Investigational Site Zwijndrecht
Spain Novo Nordisk Investigational Site Alcira
Spain Novo Nordisk Investigational Site Barcelona
Spain Novo Nordisk Investigational Site Gijón
Spain Novo Nordisk Investigational Site Majadahonda
Spain Novo Nordisk Investigational Site Palma de Mallorca
Spain Novo Nordisk Investigational Site Partida de Bacarot
Spain Novo Nordisk Investigational Site Pontevedra
Spain Novo Nordisk Investigational Site Reus
Spain Novo Nordisk Investigational Site San Juan
Spain Novo Nordisk Investigational Site Sevilla
Switzerland Novo Nordisk Investigational Site Interlaken-Unterseen
Switzerland Novo Nordisk Investigational Site Olten
Switzerland Novo Nordisk Investigational Site Zürich
United Kingdom Novo Nordisk Investigational Site Aberdeen
United Kingdom Novo Nordisk Investigational Site Bath
United Kingdom Novo Nordisk Investigational Site Belfast
United Kingdom Novo Nordisk Investigational Site Birmingham
United Kingdom Novo Nordisk Investigational Site Bradford-on-Avon
United Kingdom Novo Nordisk Investigational Site Guildford
United Kingdom Novo Nordisk Investigational Site Hull
United Kingdom Novo Nordisk Investigational Site Northampton
United Kingdom Novo Nordisk Investigational Site Salford
United Kingdom Novo Nordisk Investigational Site Swansea
United Kingdom Novo Nordisk Investigational Site Trowbridge
United Kingdom Novo Nordisk Investigational Site Trowbridge
United Kingdom Novo Nordisk Investigational Site Wirral, Merseyside
United Kingdom Novo Nordisk Investigational Site York

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Austria,  Finland,  France,  Germany,  Ireland,  Netherlands,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment difference in HbA1c After 26 weeks
Secondary Adverse events For the duration of the trial
Secondary Body weight For the duration of the trial
Secondary Lung function For the duration of the trial
Secondary Blood glucose For the duration of the trial
Secondary Hypoglycaemia For the duration of the trial
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2